02:00 PM EDT, 05/01/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our 12-month target price to CAD229 from CAD188, based on 22x our 2026 EPS estimate of CAD10.42 (up from CAD10.07). We also raise our 2025 EPS estimate to CAD9.59 from CAD9.38. This compares to the five-year average forward P/E of 17x. We note L last traded at a 23x one-year forward P/E back in the early 2000s. We believe the premium valuation is warranted given strong top- and bottom-line growth trends and robust expansion plans. Notably, 80 new stores (50 hard discount stores) and 100 new pharmacy care clinics are expected in 2025, following the addition of 50+ food/drug retail stores and nearly 80 clinics in 2024. L's Q1 results were strong and build on the momentum from last year. We believe L is well positioned to deliver another year of double-digit EPS growth, supported by strong revenue trends, stable margins, and continued share repurchases. We also think L is capitalizing on the "Buy Canadian" movement by labeling domestic products and highlighting products that face a direct tariff.